About
Founded in August 2022 as a spin-off from National Yang-Ming Chiao-Tung University, TCPC aims to mass-produce high-quality iPS cells. Leveraging Taiwan’s semiconductor-scale manufacturing expertise and partnering with Kyoto University’s CiRA Foundation, the company develops cost-effective and standardized cell production processes. In April 2023, TCPC signed a letter of intent with CiRA Foundation to accelerate industrial and clinical adoption of iPS cells in regenerative medicine.
0 responses to “Transformative Cell Processing Company”